TAK vs ZTS: Takeda Pharmaceutical Co Ltd ADR and Zoetis compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Takeda Pharmaceutical Co Ltd ADR is the larger company, worth $59.3B, about 1.8 times Zoetis.
- Takeda Pharmaceutical Co Ltd ADR grew revenue faster over the last year (+7.5% vs -0.2%).
- On earnings, Zoetis is the cheaper stock (13.0x vs 49.4x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | TAK | ZTS |
|---|---|---|
| Market cap | $59.3B | $33.3B |
| Share price | $18.73 | $74.81 |
| Revenue (last fiscal year) | $4.58T | $9.5B |
| Free cash flow (last fiscal year) | $709.3B | $2.3B |
| Revenue growth, last year | +7.5% | -0.2% |
| Revenue growth per year, last 5 fiscal years | +9.4% | +5.0% |
| Operating margin | 7.5% | — |
| Net margin | 2.4% | 27.5% |
| Return on equity | 1.6% | 83.1% |
| P/E (trailing) | 49.4x | 13.0x |
| Price / free cash flow | 0.08x | 14.6x |
| EV / EBITDA | 9.37x | 10.0x |
| FCF growth the price implies | — | 0.86% |
| Dividend yield | 3.5% | 2.6% |
| Debt / equity | 1.05x | 3.79x |
| Fundamental grade | C | C |
| Superinvestors holding it | 3 | 9 |
| Insider purchases, last 12 months | 0 | 10 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Takeda Pharmaceutical Co Ltd ADR
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $3.20T | $774.5B | 15.9% |
| 2022 | $3.57T | $937.1B | 12.9% |
| 2023 | $4.03T | $343.5B | 12.2% |
| 2024 | $4.26T | $235.6B | 5.0% |
| 2025 | $4.58T | $709.3B | 7.5% |
Zoetis
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $7.8B | $1.7B | — |
| 2022 | $8.1B | $1.3B | — |
| 2023 | $8.5B | $1.6B | — |
| 2024 | $9.3B | $2.3B | — |
| 2025 | $9.5B | $2.3B | — |
Where the revenue comes from
Takeda Pharmaceutical Co Ltd ADR · by products, 2026
ENTYVIO$958.0B21%
Immunoglobulin$790.6B18%
TAKHZYRO$223.9B5%
Others$208.0B5%
VYVANSE/ELVANSE$203.2B5%
GATTEX/REVESTIVE$145.7B3%
Zoetis · by products, 2025
Companion Animal$6.6B70%
Livestock$2.8B29%
Contract Manufacturing and Human Health Diagnostics$116M1%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open TAK in InvestinglyQuestions
Which is bigger, Takeda Pharmaceutical Co Ltd ADR or Zoetis?
Takeda Pharmaceutical Co Ltd ADR (TAK), at $59.3B against $33.3B.
Is TAK or ZTS cheaper?
By trailing P/E, Zoetis (13.0x) is cheaper than Takeda Pharmaceutical Co Ltd ADR (49.4x). A lower multiple can also mean the market expects less growth.
Which grows faster, TAK or ZTS?
Takeda Pharmaceutical Co Ltd ADR: revenue grew +7.5% over the last year, against -0.2%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.